Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 4/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 8/20 | 0.47 |
| ▸ | MIF | P14174 | 5/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | BACH1 | O14867 | 1/20 | 0.44 |
| ▸ | MAFK | O60675 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulforaphane SCHEMBL17629812 | 1.00 | NAAA (0.50) | NAAATRPA1MIFKEAP1NFE2L2 | |
| Sulforaphane SCHEMBL105203 | 1.00 | NAAA (0.50) | NAAATRPA1MIFKEAP1NFE2L2 | |
| Sulforaphane SCHEMBL20855320 | 1.00 | NAAA (0.50) | NAAATRPA1MIFKEAP1NFE2L2 | |
| Sulforaphane SCHEMBL105202 | 1.00 | NAAA (0.50) | NAAATRPA1MIFKEAP1NFE2L2 | |
| Sulforaphane SCHEMBL15822685 | 1.00 | NAAA (0.50) | NAAATRPA1MIFKEAP1NFE2L2 | |
| SCHEMBL25332541 | 0.98 | NAAA (0.54) | NAAATRPA1MIFKEAP1NFE2L2 | |
| SCHEMBL1607124 | 0.98 | NAAA (0.54) | NAAATRPA1MIFKEAP1NFE2L2 | |
| SCHEMBL14933784 | 0.98 | NAAA (0.54) | NAAATRPA1MIFKEAP1NFE2L2 | |
| SCHEMBL2485837 | 0.98 | NAAA (0.54) | NAAATRPA1MIFKEAP1NFE2L2 | |
| SCHEMBL106183 | 0.98 | NAAA (0.54) | NAAATRPA1MIFKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569523-B2 | Engineered therapeutic probiotic system and method | CHANG MATTHEW WOOK (SG) | 2026-03-10 | — | — | US | disclosed |
| US-20260061061-A1 | NON-ACTIVATED, AMORPHOUS, pH NEUTRAL, TWO-PART BEDSIDE-READY CLAY DELIVERY SYSTEM THAT TREATS PATHOGEN INFECTIONS IN HUMANS AND ANIMALS | MCCORD DARLENE E (US) | 2026-03-05 | — | — | US | disclosed |
| US-12478681-B2 | Non-activated, amorphous, pH neutral, two-part bedside-ready clay delivery system that treats pathogen infections in humans and animals | McCord, Darlene E. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4370143-B1 | A PHARMACEUTICAL MICRONUTRIENT COMPOSITION FOR USE IN THE TREATMENT OF DEPRESSION | RATH MATTHIAS W (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250114398-A1 | COATED MEDICINAL CLAY COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS, AND DELIVERY OF CATION SOURCES AND METHODS OF USE THEREOF | MCCORD, Darlene E. | 2025-04-10 | — | — | US | disclosed |
| US-20250057906-A1 | BROCCOLI EXTRACT, NUTRACEUTICAL, AND METHODS OF TREATING INFLAMMATION AND CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-02-20 | — | — | US | disclosed |
| US-12213993-B2 | Coated medicinal clay compositions, pharmaceutical compositions, and delivery of cation sources and methods of use thereof | McCord, Darlene E. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20250011881-A1 | MYC-HSF1 DUAL AMPLIFICATION AS A BIOMARKER FOR CANCER TREATMENT | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-01-09 | — | — | US | disclosed |
| US-20240358745-A1 | COMPOSITIONS AND METHODS OF DISSOLVING BIOFILM TO PROMOTE WOUND HEALING | McCord Research, Inc. | 2024-10-31 | — | — | US | disclosed |
| WO-2024226871-A1 | COMPOSITIONS AND METHODS OF DISSOLVING BIOFILM TO PROMOTE WOUND HEALING | MCCORD DARLENE E (US) | 2024-10-31 | — | — | WO | disclosed |
| US-11419847-B2 | Pharmaceutical micronutrient composition and its use to simultaneously inhibit multiple cellular mechanisms of infectivity caused by coronavirus, its variants and mutants | Rath, Matthias W. (US) | 2022-08-23 | — | — | US | disclosed |
| WO-2022173456-A1 | A PHARMACEUTICAL MICRONUTRIENT COMPOSITION AND ITS USE TO SIMULTANEOUSLY INHIBIT MULTIPLE CELLULAR MECHANISMS OF INFECTIVITY CAUSED BY CORONAVIRUS, ITS VARIANTS AND MUTANTS | RATH MATTHIAS W (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-4013372-A1 | NON-ACTIVATED, AMORPHOUS, PH NEUTRAL, TWO-PART BEDSIDE-READY CLAY DELIVERY SYSTEM THAT TREATS PATHOGEN INFECTIONS IN HUMANS AND ANIMALS | McCord, Darlene E. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220160804-A1 | USE OF LAURUS NOBILIS EXTRACT FRACTIONS TO PROTECT AGAINST AIR POLLUTION RELATED DISEASES | DSM IP ASSETS B.V. (NL) | 2022-05-26 | — | — | US | disclosed |
| US-11304922-B1 | Pharmaceutical micronutrient composition for simultaneously treating nervous system function, cognitive ability and response to stressors | Rath, Matthias W. (US) | 2022-04-19 | — | — | US | disclosed |
| US-11304921-B1 | Pharmaceutical micronutrient composition and its use to simultaneously treat nervous system function, cognitive ability and response to stressors | Rath, Matthias W. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20220095666-A1 | NUTRITIONAL COMPOSITIONS CONTAINING BUTYRATE AND USES THEREOF | MEAD JOHNSON NUTRITION COMPANY (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2022034549-A1 | MICRONUTRIENT COMBINATION TO INHIBIT CORONAVIRUS CELL INFECTION | RATH MATTHIAS W (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20220047545-A1 | Micronutrient combination to inhibit coronavirus cell infection | Rath, Matthias W (US) | 2022-02-17 | — | — | US | disclosed |
| US-11234952-B1 | Pharmaceutical micronutrient composition and its use to simultaneously improve nervous system function, cognitive ability and response to stressors | Rath, Matthias W. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114398-A1 | COATED MEDICINAL CLAY COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS, AND DELIVERY OF CATION SOURCES AND METHODS OF USE THEREOF | SLC9A3, SLC11A2, SLC9A2 | NAAA 1467/4885TRPA1 126/4885MIF 376/4885 |
| US-20220160804-A1 | USE OF LAURUS NOBILIS EXTRACT FRACTIONS TO PROTECT AGAINST AIR POLLUTION RELATED DISEASES | NOS2, NOS1, NOS3 | NAAA 3789/4885TRPA1 267/4885MIF 254/4885 |
| US-12213993-B2 | Coated medicinal clay compositions, pharmaceutical compositions, and delivery of cation sources and methods of use thereof | SLC9A3, SLC11A2, SLC9A2 | NAAA 1467/4885TRPA1 126/4885MIF 376/4885 |
| US-12569523-B2 | Engineered therapeutic probiotic system and method | SI, MGST1, FABP2 | NAAA 2618/4885TRPA1 601/4885MIF 305/4885 |
| US-12478681-B2 | Non-activated, amorphous, pH neutral, two-part bedside-ready clay delivery system that treats pathogen infections in humans and animals | NONO, CUTA, LRBA | NAAA 1763/4885TRPA1 3211/4885MIF 1457/4885 |
| US-20240358745-A1 | COMPOSITIONS AND METHODS OF DISSOLVING BIOFILM TO PROMOTE WOUND HEALING | ORAI1, NONO, CFTR | NAAA 1837/4885TRPA1 82/4885MIF 120/4885 |
| US-20260061061-A1 | NON-ACTIVATED, AMORPHOUS, pH NEUTRAL, TWO-PART BEDSIDE-READY CLAY DELIVERY SYSTEM THAT TREATS PATHOGEN INFECTIONS IN HUMANS AND ANIMALS | CUTA, NONO, SLC11A2 | NAAA 2143/4885TRPA1 1633/4885MIF 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.